Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
Incyte looks to widen Monjuvi's net with label expansion bid after phase 3 lymphoma win
Aug 15 (Reuters) - Incyte (INCY.O), opens new tab said on Thursday its drug met the main goal in a late-stage trial evaluating it in patients with a form of blood cancer.
The new addition comes from axatilimab, a CSF-1R inhibitor partnered with Syndax Pharmaceuticals. Wednesday, the drug received an FDA approval under the brand name Niktimvo to treat chronic GVHD (cGVHD) in patients who’ve failed at least two prior lines of systemic therapy.
Incyte touts 2 trial wins for PD-1 drug Zynyz, eyes comeback in anal cancer
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Incyte to Report Second Quarter Financial Results
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Silence Therapeutics has spoken up about its phase 1 polycythemia vera (PV) clinical trial, providing an early look at how its siRNA prospect may match up to rivals from Incyte and Takeda. nnPV patients undergo regular blood draws, a procedure known as a phlebotomy, to reduce the number of blood cells and decrease blood volume. At baseline, all subjects in Silence’s trial had undergone at least three phlebotomies in the past six months or five phlebotomies in the past year. In total, the participants underwent 59 blood draws in the six months before starting the study.
Incyte Announces Final Results of Tender Offer